View ValuationVirbac 향후 성장Future 기준 점검 1/6Virbac (는) 각각 연간 10.2% 및 5.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.9% 로 예상됩니다.핵심 정보10.2%이익 성장률10.00%EPS 성장률Pharmaceuticals 이익 성장14.5%매출 성장률5.2%향후 자기자본이익률12.85%애널리스트 커버리지Good마지막 업데이트22 May 2026최근 향후 성장 업데이트공시 • Jan 20Virbac SA Provides Earnings Guidance for the Year 2026Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope.공시 • Oct 17Virbac SA Updates Revenue Guidance for the Year 2025Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before).공시 • Sep 13Virbac Sa Confirms Earnings Guidance for the Year 2025Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.공시 • Jan 17Virbac SA Provides Revenue Guidance for the Year 2025Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.공시 • Jul 17Virbac SA Revises Earnings Guidance for the Fiscal Year 2024Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%.공시 • Jan 18Virbac SA Provides Earnings Guidance for the Year 2024Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023.모든 업데이트 보기Recent updates공시 • May 26Virbac SA, Annual General Meeting, Jun 29, 2026Virbac SA, Annual General Meeting, Jun 29, 2026. Location: 13e rue lid, carros France공시 • Mar 18Virbac Sa Proposes Dividend for the Fiscal Year 2025Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year.공시 • Jan 20Virbac SA Provides Earnings Guidance for the Year 2026Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope.공시 • Dec 17Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million.Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million on December 16, 2025. The transaction is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac. Thyronorm has in-market sales of approximately €27 million. Virbac SA (ENXTPA:VIRP) completed the acquisition of Thyronorm from Norbrook Laboratories Limited on December 16, 2025.공시 • Dec 08Virbac SA to Report First Half, 2026 Results on Sep 17, 2026Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026공시 • Oct 17Virbac SA Updates Revenue Guidance for the Year 2025Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before).공시 • Sep 13Virbac Sa Confirms Earnings Guidance for the Year 2025Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.공시 • Jun 21Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025Virbac SA announced the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young, then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance.공시 • May 13Virbac SA, Annual General Meeting, Jun 19, 2025Virbac SA, Annual General Meeting, Jun 19, 2025. Location: 13e rue lid, carros France공시 • Mar 14+ 1 more updateVirbac SA Recommends Dividend Distribution for the 2024Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2024 fiscal year.공시 • Jan 17Virbac SA Provides Revenue Guidance for the Year 2025Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.공시 • Dec 13+ 1 more updateVirbac SA to Report Q4, 2025 Results on Jan 15, 2026Virbac SA announced that they will report Q4, 2025 results After-Market on Jan 15, 2026공시 • Dec 04Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S.Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024. Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024.공시 • Jul 17Virbac SA Revises Earnings Guidance for the Fiscal Year 2024Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%.공시 • Jul 08Virbac Sa Announces Chief Executive Officer ChangesVirbac SA announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. About Habib Ramdani: Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020.공시 • Apr 03Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor. Virbac SA (ENXTPA:VIRP) completed the acquisition of Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) on April 1, 2024.공시 • Mar 08Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor.공시 • Jan 18Virbac SA Provides Earnings Guidance for the Year 2024Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023.공시 • Dec 23+ 2 more updatesVirbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024Virbac SA announced that they will report fiscal year 2023 results After-Market on Mar 19, 2024공시 • Sep 29Virbac SA Confirms Revenue Forecasts for the Year 2023Virbac SA confirmed revised revenue forecasts for the year 2023. The company confirms revised forecasts with revenue growth at constant rates and scope expected in a range between 0% and 4%.공시 • Dec 15Virbac SA to Report First Half, 2023 Results on Sep 14, 2023Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023공시 • Dec 14+ 1 more updateVirbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023Virbac SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Mar 23, 2023이익 및 매출 성장 예측OTCPK:VRBC.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,715210168275612/31/20271,643192122247812/31/20261,55816772211412/31/20251,46515197199N/A9/30/20251,44914293197N/A6/30/20251,43313388195N/A3/31/20251,415139106200N/A12/31/20241,397145124204N/A9/30/20241,36814399171N/A6/30/20241,33914174139N/A3/31/20241,29313166129N/A12/31/20231,24712159119N/A9/30/20231,22912069124N/A6/30/20231,21011978129N/A3/31/20231,21312162114N/A12/31/20221,2161224599N/A9/30/20221,1841203891N/A6/30/20221,1511193184N/A3/31/20221,10711657107N/A12/31/20211,06411383130N/A9/30/20211,02513780122N/A6/30/202198516177113N/A3/31/202196014883116N/A12/31/202093413690119N/A9/30/2020944104106133N/A6/30/202095372123146N/A3/31/202094662116139N/A12/31/201993852109132N/A9/30/201992143N/A119N/A6/30/201990334N/A106N/A3/31/201988627N/A95N/A12/31/201886920N/A84N/A9/30/20188628N/A93N/A6/30/2018854-4N/A103N/A3/31/2018858-3N/A105N/A12/31/2017862-3N/A108N/A9/30/201787116N/A112N/A6/30/201787935N/A117N/A3/31/201787635N/A130N/A12/31/201687235N/A142N/A9/30/201686130N/A119N/A6/30/201685026N/A95N/A3/31/201685118N/A71N/A12/31/20158539N/A46N/A9/30/201584621N/A59N/A6/30/201583932N/A72N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VRBC.F 의 연간 예상 수익 증가율(10.2%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: VRBC.F 의 연간 수익(10.2%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: VRBC.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: VRBC.F 의 수익(연간 5.2%)이 US 시장(연간 11.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: VRBC.F 의 수익(연간 5.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VRBC.F의 자본 수익률은 3년 후 12.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 21:17종가2026/05/12 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Virbac SA는 12명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Delphine Le LouetBernsteinLaurent GelebartBNP ParibasArnaud CadartCIC Market Solutions (ESN)9명의 분석가 더 보기
공시 • Jan 20Virbac SA Provides Earnings Guidance for the Year 2026Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope.
공시 • Oct 17Virbac SA Updates Revenue Guidance for the Year 2025Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before).
공시 • Sep 13Virbac Sa Confirms Earnings Guidance for the Year 2025Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.
공시 • Jan 17Virbac SA Provides Revenue Guidance for the Year 2025Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.
공시 • Jul 17Virbac SA Revises Earnings Guidance for the Fiscal Year 2024Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%.
공시 • Jan 18Virbac SA Provides Earnings Guidance for the Year 2024Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023.
공시 • May 26Virbac SA, Annual General Meeting, Jun 29, 2026Virbac SA, Annual General Meeting, Jun 29, 2026. Location: 13e rue lid, carros France
공시 • Mar 18Virbac Sa Proposes Dividend for the Fiscal Year 2025Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2025 fiscal year.
공시 • Jan 20Virbac SA Provides Earnings Guidance for the Year 2026Virbac SA provided earnings guidance for the year 2026. 2026 guidance: (incl. Thyronorm acquisition impact): revenue growth expected to be between 5.5% and 7.5% at constant rates and scope.
공시 • Dec 17Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million.Virbac SA (ENXTPA:VIRP) acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at €100 million on December 16, 2025. The transaction is expected to be accretive to Virbac Group sales growth and EBITDA margin from year 1. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) before being gradually taken over by Virbac. Thyronorm has in-market sales of approximately €27 million. Virbac SA (ENXTPA:VIRP) completed the acquisition of Thyronorm from Norbrook Laboratories Limited on December 16, 2025.
공시 • Dec 08Virbac SA to Report First Half, 2026 Results on Sep 17, 2026Virbac SA announced that they will report first half, 2026 results on Sep 17, 2026
공시 • Oct 17Virbac SA Updates Revenue Guidance for the Year 2025Virbac SA updated revenue guidance for the year 2025. For the year, the company expects sales momentum observed in the third quarter, revenue growth at constant exchange rates and scope is now expected to be between 5.5% and 7.5% (against 4 to 6% before).
공시 • Sep 13Virbac Sa Confirms Earnings Guidance for the Year 2025Virbac SA confirmed earnings guidance for the year 2025. For the year, the company confirms outlook for revenue growth at constant rates and scope of between 4% and 6%. The impact of the Sasaeah acquisition is expected to represent 1 point of additional growth in 2025.
공시 • Jun 21Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025Virbac SA announced the appointment of Paul Martingell as the chief executive officer of the Virbac group, effective September 1, 2025. Paul Martingell, 45, is recognized as a leader who has demonstrated his ability to engage and inspire international teams, manage complexity, and create value for all stakeholders. He holds an MBA with distinction in Mergers and Acquisitions and is a Chartered Accountant in the United Kingdom. He has over 25 years of extensive international experience, particularly in consumer health, consumer goods, and pharmaceuticals. His professional journey is marked by roles of increasing responsibility in Europe, Asia, and Latin America, first at Ernst & Young, then at Reckitt Benckiser and Novartis Consumer Healthcare. For the past eleven years, he has been part of the executive committee that oversaw the merger of Boehringer Ingelheim's and Sanofi's Consumer Healthcare businesses. During this time, he led key regions and served as chief growth officer. For the last three years, he has held the position of senior vice president, region head for Europe and Latin America, a region generating close to 3 billion euros in revenue. He was also part of the leadership team that successfully completed the spin-off of Opella. Paul is a recognized leader for his ability to develop diverse and agile teams, lead growth and learning-oriented cultures. He has proven his ability in building collective visions and leading successful transformations in operational roles, to deliver superior performance.
공시 • May 13Virbac SA, Annual General Meeting, Jun 19, 2025Virbac SA, Annual General Meeting, Jun 19, 2025. Location: 13e rue lid, carros France
공시 • Mar 14+ 1 more updateVirbac SA Recommends Dividend Distribution for the 2024Virbac SA announced at the next shareholders' meeting, a net dividend per share of €1.45 will be recommended for distribution for the 2024 fiscal year.
공시 • Jan 17Virbac SA Provides Revenue Guidance for the Year 2025Virbac SA provided revenue guidance for the year 2025. For the year 2024, the company currently anticipate revenue growth at constant scope and exchange rates between 4% and 6%.
공시 • Dec 13+ 1 more updateVirbac SA to Report Q4, 2025 Results on Jan 15, 2026Virbac SA announced that they will report Q4, 2025 results After-Market on Jan 15, 2026
공시 • Dec 04Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S.Virbac SA (ENXTPA:VIRP) acquired Mopsan Veteriner Urunleri A.S. on December 2, 2024. Virbac SA (ENXTPA:VIRP) completed the acquisition of Mopsan Veteriner Urunleri A.S. on December 2, 2024.
공시 • Jul 17Virbac SA Revises Earnings Guidance for the Fiscal Year 2024Virbac SA revised earnings guidance for the fiscal year 2024. For the year, The company anticipates revenue growth between 7% and 9%.
공시 • Jul 08Virbac Sa Announces Chief Executive Officer ChangesVirbac SA announces the resignation of Sébastien Huron from his position as chief executive officer. He will leave the Virbac Group's executive management by September 30, 2024, to take a break from his professional life.The board of directors has decided to appoint Habib Ramdani, currently chief financial officer and deputy chief executive officer, as interim CEO, to replace Sébastien Huron, while the appointments and compensation committee recruits the next chief executive officer. Backed by the board of directors, Habib will be able to count on the full support of the Group executive committee in executing the roadmap of our Virbac 2030 project. About Habib Ramdani: Habib Ramdani is a graduate of the École Centrale de Paris. He started his career in 1999 as a strategy consultant at the Boston Consulting Group (BCG). He joined the pharmaceutical company Ipsen in 2002 where he quickly became Group Strategic Planning director. He was then appointed Group Controller and oversaw the Group's Management Control department as well as Ipsen's Group Financial Accounting and Consolidation department before taking over the Finance and Strategy department of the North American subsidiaries while based in New Jersey, USA. He joined the Virbac Group in 2016 as chief financial officer and member of the executive board, before being appointed deputy chief executive officer and member of the Group executive committee on December 15, 2020.
공시 • Apr 03Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor. Virbac SA (ENXTPA:VIRP) completed the acquisition of Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) on April 1, 2024.
공시 • Mar 08Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million on March 6, 2024. The annual revenues of Sasaea Holdings Co., Ltd. were about €75 million. The transaction is expected to close by the beginning of April 2024. Nomura acted as financial advisor to Virbac in this transaction and Hogan Lovells acted as its legal advisor.
공시 • Jan 18Virbac SA Provides Earnings Guidance for the Year 2024Virbac SA provided earnings guidance for the year 2024. For the year 2024, the company confirm a revenue growth target between 4% and 6% at constant rates and scope, as well as a ratio of "current operating income before amortisation of assets resulting from acquisitions” to “revenue” around 15% at constant exchange rates. As announced in previous communications, this level of profitability takes into account a deliberate further acceleration in R&D investments, representing almost +0.5 points as a percentage of revenue compared with 2023.
공시 • Dec 23+ 2 more updatesVirbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024Virbac SA announced that they will report fiscal year 2023 results After-Market on Mar 19, 2024
공시 • Sep 29Virbac SA Confirms Revenue Forecasts for the Year 2023Virbac SA confirmed revised revenue forecasts for the year 2023. The company confirms revised forecasts with revenue growth at constant rates and scope expected in a range between 0% and 4%.
공시 • Dec 15Virbac SA to Report First Half, 2023 Results on Sep 14, 2023Virbac SA announced that they will report first half, 2023 results on Sep 14, 2023
공시 • Dec 14+ 1 more updateVirbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023Virbac SA announced that they will report fiscal year 2022 results at 5:40 PM, Central European Standard Time on Mar 23, 2023